MX2022012404A - Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. - Google Patents

Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.

Info

Publication number
MX2022012404A
MX2022012404A MX2022012404A MX2022012404A MX2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A
Authority
MX
Mexico
Prior art keywords
hepe
compositions
treating
related diseases
hematologic disorders
Prior art date
Application number
MX2022012404A
Other languages
English (en)
Inventor
David Coughlan
John Climax
Moayed Hamza
Markus Weissbach
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MX2022012404A publication Critical patent/MX2022012404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con métodos para tratar o prevenir trastornos hematológicos mediante el suministro de 15-HEPE o composiciones del mismo.
MX2022012404A 2020-04-03 2020-04-03 Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. MX2022012404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/059682 WO2021197639A1 (en) 2020-04-03 2020-04-03 Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases

Publications (1)

Publication Number Publication Date
MX2022012404A true MX2022012404A (es) 2023-02-09

Family

ID=70189967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012404A MX2022012404A (es) 2020-04-03 2020-04-03 Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.

Country Status (10)

Country Link
EP (1) EP4125854A1 (es)
JP (1) JP2023528562A (es)
KR (1) KR20220163468A (es)
CN (1) CN115715192A (es)
AU (1) AU2020440809A1 (es)
BR (1) BR112022020012A2 (es)
CA (1) CA3179158A1 (es)
IL (1) IL297114A (es)
MX (1) MX2022012404A (es)
WO (1) WO2021197639A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233173A (zh) * 2020-10-30 2022-09-01 愛爾蘭商Ｄｓ生物製藥有限公司 包括１５－ＨＥＴｒＥ之醫藥組合物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344226T1 (de) * 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物

Also Published As

Publication number Publication date
EP4125854A1 (en) 2023-02-08
WO2021197639A1 (en) 2021-10-07
IL297114A (en) 2022-12-01
JP2023528562A (ja) 2023-07-05
CN115715192A (zh) 2023-02-24
AU2020440809A1 (en) 2022-11-10
CA3179158A1 (en) 2021-10-07
BR112022020012A2 (pt) 2022-12-13
KR20220163468A (ko) 2022-12-09

Similar Documents

Publication Publication Date Title
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2023001876A (es) Derivados de rapamicina.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550872A1 (en) Therapeutic compounds
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
MX2022014924A (es) Moduladores de il-17a.
MX2022014925A (es) Moduladores de il-17a.
CR20220570A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t